NBRC Pharmacology Practice Exam

The choice of long-acting beta-agonists (LABAs) and leukotriene receptor antagonists is effective in reducing the frequency of asthma attacks because both classes of medications address the underlying inflammation and bronchoconstriction associated with chronic asthma.

Long-acting beta-agonists work by relaxing the muscles around the airways, which helps to keep them open for a prolonged period and allows for better airflow. They are typically used in conjunction with inhaled corticosteroids for more persistent cases of asthma, offering a dual approach to both prevention of symptoms and management of airflow limitation.

Leukotriene receptor antagonists, on the other hand, work by blocking the action of leukotrienes, which are inflammatory mediators that can lead to bronchoconstriction and mucus production. By inhibiting these mediators, these drugs can decrease inflammation and prevent asthma symptoms, thus effectively reducing the frequency of asthma attacks.

Together, these two classes provide a comprehensive method for managing asthma over a long term, focusing on both preventing acute exacerbations and improving overall lung function.